79 related articles for article (PubMed ID: 8782010)
1. HIV-1 dynamics in vivo.
Ho DD
J Biol Regul Homeost Agents; 1995; 9(3):76-7. PubMed ID: 8782010
[No Abstract] [Full Text] [Related]
2. Rapid turnover of plasma virions and CD4 lymphocytes in HIV-1 infection.
Ho DD; Neumann AU; Perelson AS; Chen W; Leonard JM; Markowitz M
Nature; 1995 Jan; 373(6510):123-6. PubMed ID: 7816094
[TBL] [Abstract][Full Text] [Related]
3. The current role of ritonavir-boosted protease inhibitors in the management of HIV infection.
Wilkins E
J HIV Ther; 2008 Mar; 13(1):9-18. PubMed ID: 18953268
[No Abstract] [Full Text] [Related]
4. HIV-1 dynamics in vivo: implications for therapy.
Simon V; Ho DD
Nat Rev Microbiol; 2003 Dec; 1(3):181-90. PubMed ID: 15035022
[TBL] [Abstract][Full Text] [Related]
5. [Viral dynamics in the course of HIV-1 infection: pathogenetic features and new therapeutic prospects].
Marcello A; Giacca M
Pathologica; 2000 Aug; 92(4):291-3. PubMed ID: 11029891
[No Abstract] [Full Text] [Related]
6. Effect of interleukin-2 on the pool of latently infected, resting CD4+ T cells in HIV-1-infected patients receiving highly active anti-retroviral therapy.
Chun TW; Engel D; Mizell SB; Hallahan CW; Fischette M; Park S; Davey RT; Dybul M; Kovacs JA; Metcalf JA; Mican JM; Berrey MM; Corey L; Lane HC; Fauci AS
Nat Med; 1999 Jun; 5(6):651-5. PubMed ID: 10371503
[TBL] [Abstract][Full Text] [Related]
7. Predictors of virologic response to ritonavir-boosted protease inhibitors.
Marcelin AG; Flandre P; Peytavin G; Calvez V
AIDS Rev; 2005; 7(4):225-32. PubMed ID: 16425962
[TBL] [Abstract][Full Text] [Related]
8. [HIV-1 quantitative dynamics in vivo: a review of mathematical models].
Le Corfec E; Rouzioux C; Costagliola D
Rev Epidemiol Sante Publique; 2000 Apr; 48(2):168-81. PubMed ID: 10804426
[TBL] [Abstract][Full Text] [Related]
9. HIV-1 and HAART: a time to cure, a time to kill.
Saag MS; Kilby JM
Nat Med; 1999 Jun; 5(6):609-11. PubMed ID: 10371490
[No Abstract] [Full Text] [Related]
10. Decay characteristics of HIV-1-infected compartments during combination therapy.
Perelson AS; Essunger P; Cao Y; Vesanen M; Hurley A; Saksela K; Markowitz M; Ho DD
Nature; 1997 May; 387(6629):188-91. PubMed ID: 9144290
[TBL] [Abstract][Full Text] [Related]
11. Genotypic resistance analysis of the virological response to fosamprenavir-ritonavir in protease inhibitor-experienced patients in CONTEXT and TRIAD clinical trials.
Marcelin AG; Flandre P; Molina JM; Katlama C; Yeni P; Raffi F; Antoun Z; Ait-Khaled M; Calvez V
Antimicrob Agents Chemother; 2008 Dec; 52(12):4251-7. PubMed ID: 18852278
[TBL] [Abstract][Full Text] [Related]
12. Ability of different lopinavir genotypic inhibitory quotients to predict 48-week virological response in highly treatment-experienced HIV-infected patients receiving lopinavir/ritonavir.
Gianotti N; Galli L; Danise A; Hasson H; Boeri E; Lazzarin A; Castagna A
J Med Virol; 2006 Dec; 78(12):1537-41. PubMed ID: 17063520
[TBL] [Abstract][Full Text] [Related]
13. Efficacy and safety of indinavir/ritonavir 400/100 mg twice daily plus two nucleoside analogues in treatment-naive HIV-1-infected patients with CD4+ T-cell counts <200 cells/mm3: 96-week outcomes.
Mootsikapun P; Chetchotisakd P; Anunnatsiri S; Boonyaprawit P
Antivir Ther; 2005; 10(8):911-6. PubMed ID: 16430196
[TBL] [Abstract][Full Text] [Related]
14. Limited penetration of lopinavir and ritonavir in the genital tract of men infected with HIV-1 in Brazil.
Vergara TR; Estrela RC; Suarez-Kurtz G; Schechter M; Cerbino-Neto J; Barroso PF
Ther Drug Monit; 2006 Apr; 28(2):175-9. PubMed ID: 16628127
[TBL] [Abstract][Full Text] [Related]
15. Virological responses to atazanavir-ritonavir-based regimens: resistance-substitutions score and pharmacokinetic parameters (Reyaphar study).
Pellegrin I; Breilh D; Ragnaud JM; Boucher S; Neau D; Fleury H; Schrive MH; Saux MC; Pellegrin JL; Lazaro E; Vray M
Antivir Ther; 2006; 11(4):421-9. PubMed ID: 16856615
[TBL] [Abstract][Full Text] [Related]
16. Efficacy and safety of ritonavir-boosted dual protease inhibitor therapy in antiretroviral-naive HIV-1-infected patients: the 2IP ANRS 127 study.
Landman R; Capitant C; Descamps D; Chazallon C; Peytavin G; Katlama C; Pialoux G; Bentata M; Brun-Vézinet F; Aboulker JP; Yéni P;
J Antimicrob Chemother; 2009 Jul; 64(1):118-25. PubMed ID: 19420019
[TBL] [Abstract][Full Text] [Related]
17. Dynamics of HIV replication in lymphocytes and the efficacy of protease inhibitors.
Bermejo M; Sánchez-Palomino S; Usán L; Alcamí J
J Med Virol; 2004 Aug; 73(4):502-7. PubMed ID: 15221892
[TBL] [Abstract][Full Text] [Related]
18. Effect of zidovudine resistance mutations on virologic response to treatment with zidovudine-lamivudine-ritonavir: genotypic analysis of human immunodeficiency virus type 1 isolates from AIDS clinical trials group protocol 315.ACTG Protocol 315 Team.
Kuritzkes DR; Sevin A; Young B; Bakhtiari M; Wu H; St Clair M; Connick E; Landay A; Spritzler J; Kessler H; Lederman MM
J Infect Dis; 2000 Feb; 181(2):491-7. PubMed ID: 10669331
[TBL] [Abstract][Full Text] [Related]
19. Stavudine, lamivudine plus novel protease inhibitor therapy in antiretroviral-naive HIV-infected individuals treated for 24 weeks.
Murphy RL
Antivir Ther; 1999; 4 Suppl 3():85-7. PubMed ID: 16021877
[TBL] [Abstract][Full Text] [Related]
20. [Efficacy of ritonavir in HIV positive patients pretreated with nucleoside analogues].
Gómez-Cano M; Soriano V; Polo R; Valencia E; Adrados M; González-Lahoz J
An Med Interna; 1998 Feb; 15(2):83-6. PubMed ID: 9542203
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
